ThromboGenics Receives Notice From FDA of Advisory Committee Meeting for Ocriplasmin

ThromboGenics Receives Notice From FDA of Advisory Committee Meeting for Ocriplasmin PR Newswire LEUVEN, Belgium, June 7, 2012 LEUVEN, Belgium, June 7, 2012 /PRNewswire/ -- Meeting scheduled for 26 July 2012 ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug